- Home
- GMAB vs RIVN Comparison
GMAB vs RIVN Comparison
Compare GMAB & RIVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- RIVN
- Stock Information
- Founded
- GMAB 1999
- RIVN 2009
- Country
- GMAB Denmark
- RIVN United States
- Employees
- GMAB N/A
- RIVN N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- RIVN Auto Manufacturing
- Sector
- GMAB Health Care
- RIVN Consumer Discretionary
- Exchange
- GMAB Nasdaq
- RIVN Nasdaq
- Market Cap
- GMAB 15.0B
- RIVN 13.3B
- IPO Year
- GMAB N/A
- RIVN 2021
- Fundamental
- Price
- GMAB $20.65
- RIVN $10.24
- Analyst Decision
- GMAB Buy
- RIVN Buy
- Analyst Count
- GMAB 8
- RIVN 23
- Target Price
- GMAB $43.00
- RIVN $15.67
- AVG Volume (30 Days)
- GMAB 1.4M
- RIVN 43.7M
- Earning Date
- GMAB 11-06-2024
- RIVN 11-07-2024
- Dividend Yield
- GMAB N/A
- RIVN N/A
- EPS Growth
- GMAB 14.35
- RIVN N/A
- EPS
- GMAB 10.80
- RIVN N/A
- Revenue
- GMAB $2,967,926,227.00
- RIVN $4,551,000,000.00
- Revenue This Year
- GMAB $30.31
- RIVN $7.44
- Revenue Next Year
- GMAB $16.49
- RIVN $18.95
- P/E Ratio
- GMAB $18.68
- RIVN N/A
- Revenue Growth
- GMAB 17.75
- RIVN 20.33
- 52 Week Low
- GMAB $20.34
- RIVN $8.26
- 52 Week High
- GMAB $32.88
- RIVN $24.62
- Technical
- Relative Strength Index (RSI)
- GMAB 29.22
- RIVN 47.41
- Support Level
- GMAB $20.34
- RIVN $9.55
- Resistance Level
- GMAB $23.47
- RIVN $10.47
- Average True Range (ATR)
- GMAB 0.46
- RIVN 0.76
- MACD
- GMAB -0.12
- RIVN -0.00
- Stochastic Oscillator
- GMAB 9.90
- RIVN 20.56
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About RIVN Rivian Automotive Inc.
Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).